Multiple sclerosis (MS) is an autoimmune disorder that targets myelin proteins and results in extensive damage in the central nervous system in the form of focal lesions as well as diffuse molecular changes. Lesions are currently detected using T1-weighted, T2-weighted, and gadolinium-enhanced magnetic resonance imaging (MRI); however, monitoring such lesions has been shown to be a poor predictor of disease progression. Chemical exchange saturation transfer (CEST) MRI is sensitive to many of the biomolecules in the central nervous system altered in MS that cannot be detected using conventional MRI. We monitored disease progression in an experimental autoimmune encephalomyelitis (EAE) model of MS using on resonance variable delay multiple pulse (onVDMP) CEST MRI. Alterations in onVDMP signal were observed in regions responsible for hindlimb function throughout the central nervous system. Histological analysis revealed glial activation in areas highlighted in onVDMP CEST MRI. onVDMP signal changes in the 3rd ventricle preceded paralysis onset that could not be observed with conventional MRI techniques. Hence, the onVDMP CEST MRI signal has potential as a novel imaging biomarker and predictor of disease progression in MS.
Introduction
The pathophysiology responsible for disability in MS is complex, involving multiple cell types and biomolecules. Activated immune cells infiltrate the central nervous system (CNS) through the blood-brainbarrier (BBB) and then migrate throughout the brain and spinal cord with the aid of the ventricular system (Hatterer et al., 2008; Kivis€ akk et al., 2003) . These cells secrete excitotoxic molecules (Pacheco et al., 2006) as well as inflammatory cytokines (Tzartos et al., 2008) that in turn activate (Murphy et al., 2010; Yi et al., 2014) and induce metabolic alterations (Zeis et al., 2015a) in local cells. This combination results in neuronal damage and death of myelinating oligodendrocytes supporting them (Pitt et al., 2000; Werner et al., 2001) . This cascade ultimately results in focal lesions or atrophy, which can be visualized using conventional magnetic resonance imaging (MRI).
Visualization of lesions using MRI has been a principle component of Abbreviations: BBB, blood-brain-barrier; DPI, days post induction; EAE, experimental autoimmune encephalomyelitis; GFAP, glial fibrillary acidic protein; MOG, myelin oligodendrocyte glycoprotein; MRI, magnetic resonance imaging; MS, multiple sclerosis; onVDMP CEST, on-resonance variable-delay multiple pulse chemical exchange saturation transfer. diagnosis and monitoring of MS for decades . Three scans are routinely performed on MS patients to detect lesions: gadolinium (Gd)-enhanced, T1-w, and T2-w MRI. Gd-enhanced MRI, which visualizes disruption of the BBB, can detect de novo lesions (Kermode et al., 1990) , although recent reports have raised toxicity and other pharmacokinetic concerns regarding its repeated (Ariyani et al., 2017; Grobner, 2006) . T1-w and T2-w MRI, which are sensitive to brain water and fat content, can visualize lesions not enhanced by gadolinium. However, meta-analyses have revealed that monitoring lesions is a poor predictor of disease progression (Goodin, 2006) , which has prompted the exploration of new techniques for monitoring MS.
Recent evidence emerging from quantitative MRI and post-mortem pathology has revealed that MS is a neurodegenerative disorder primarily consisting of widespread, diffuse damage with sporadic sclerotic lesions (Filippi and Rocca, 2005; Tovar-Moll et al., 2015; West et al., 2014) . Quantitative MRI metrics, i.e. axonal degeneration (diffusion tensor imaging), myelin content (magnetization transfer ratio imaging) and atrophy (T1-w and T2-w MRI), correlate better with disability than lesion assessment using conventional MRI, but they only partially monitor later stages of pathophysiology in MS (Harrison et al., 2013; Popescu et al., 2013) . Earlier stages of MS pathophysiology induce metabolic changes, e.g. glutamate (Tisell et al., 2013; Vercellino et al., 2007) and lactate (Nijland et al., 2014 (Nijland et al., , 2015 Zeis et al., 2015b) , which can be detected using chemical exchange saturation transfer (CEST) MRI (Cai et al., 2012; DeBrosse et al., 2016) .
CEST MRI is a promising imaging modality that can detect a multitude of biomolecules in the CNS through their exchangeable protons, e.g. amines and hydroxyls (Jones et al., 2018; Knutsson et al., 2018; van Zijl and Yadav, 2011; van Zijl et al., 2018; Sehgal et al., 2019) . CEST MRI methods have been explored pre-clinically for many neurological diseases including cancer (Kejia et al., 2015; Zhou et al., 2003 Zhou et al., , 2011 , epilepsy (Davis et al., 2015) , Alzheimer's disease (Haris et al., 2013) and Parkinson's disease (Bagga et al., 2018) . The recent development of CEST MRI methods to monitor mobile protein (By et al., 2018a; Dula et al., 2011) and glutamate (Dula et al., 2016; O'Grady et al., 2018) content in MS patients has expanded the visual information toolkit for monitoring the pathophysiological progression of lesions and cognitive decline. Here we evaluate the reproducibility and utility of the recently developed on-resonance variable delay multiple pulse (onVDMP) CEST MRI technique (Xiang et al., 2016; Xu et al., 2014 Xu et al., , 2017 to predict and monitor the progression of paralysis in chronic EAE, an animal model for primary progressive MS, and compared it to more conventional MRI techniques. We also assessed its ability to detect regions in the central nervous system prone to damage in MS and EAE.
Materials and methods

EAE induction
All animal experiments were approved by the Animal Care and Use Committee of Johns Hopkins University. Female C57Bl/6 mice (Jackson Laboratories), 6-10 weeks old, were injected s.c. With 200 μl of 0.5 mg/ ml myelin oligodendrocyte glycoprotein , Johns Hopkins Synthesis and Sequencing Facility) emulsified in incomplete Freund's adjuvant supplemented with 5 mg/ml Mycobacterium tuberculosis H37Ra. Mice were injected i.p. With 300 ng of pertussis toxin. Injections were performed on the day of induction and two days later. Three cohorts were analyzed in this manuscript. EAE-induced mice (n ¼ 4-6 per cohort) were compared to naïve mice (n ¼ 4-5) for all studies performed. Two additional controls were used to assess the effects of peripheral inflammation: mice that did not receive MOG peptide (complete Freund's adjuvant and pertussis toxin only, n ¼ 4) and mice that did not experience paralysis (subclinical EAE, n ¼ 2). Individual reporting of animal numbers has been provided in the following repository [dataset] (https://doi.org/10.17632/sr567vff6p.1).
Assessment of clinical disease progression
After immunization, mice were observed daily for clinical signs of EAE. Animal behavior was divided into six clinical stages as follows: 0 ¼ asymptomatic; 1 ¼ atonic tail; 2 ¼ partial hind limb paralysis; 3 ¼ paraplegia; 4 ¼ quadriplegia; and 5 ¼ moribund/death. Onset of disease was defined as having a paralysis score of >1.
MRI acquisition and analysis
MRI and magnetic resonance spectroscopy (MRS) were performed using a Bruker 11.7T horizontal bore spectrometer and a 20 mm surface coil with transmit/receive capabilities. Animals were anesthetized with isoflurane (1-2%). All MRI sequences were co-registered approximately 1 mm posterior from bregma (unless otherwise indicated) with a slice number ¼ 1, slice thickness ¼ 2 mm (0.7 mm to locate structures), and field of view ¼ 13 Â 13 mm to permit comparison of spatiotemporal trends in the EAE model. The following imaging sequences and scan parameters were used:
T1-weighted MRI
A fast low angle shot (FLASH) sequence was used. Scan parameters were repetition time/echo time (TR/TE) ¼ 300/6 ms, number of averages (NA) ¼ 2, and matrix size ¼ 128x128, with a total scan time of 235 s.
T2-weighted MRI
A rapid acquisition with relaxation enhancement (RARE) sequence was used. Scan parameters were TR/TE ¼ 2000/20 ms, RARE factor ¼ 8, NA ¼ 4, and matrix size ¼ 128x128, with a total scan time of 64 s.
T2*-weighted MRI
A gradient echo (GRE) sequence was used. Scan parameters were TR/ TE ¼ 800/3 ms, NA ¼ 2, and matrix size ¼ 256x256, with a total scan time of 153 s.
onVDMP CEST MRI
Scan parameters were TR/TE ¼ 5000/25 ms, RARE factor ¼ 10, NA ¼ 1, repetitions ¼ 9, B 1 ¼ 46.8 μT, 32 pulse-exchange modules with a 2 ms pulse width and eight delays (mixing times from 1.14 to 100 ms), and matrix size ¼ 128x128, with a scan time of 540 s.
2.3.5. Continuous wave (CW) and amide proton transfer (APT) CEST MRI Scan parameters were TR/TE ¼ 5000/11 ms, RARE factor ¼ 23,
sweep from À8 to þ8 ppm with 0.4 ppm increments, and matrix size ¼ 64x64, with a scan time of 210 s.
Post-mortem analysis
Mice were sacrificed 15 and 29 days after induction, perfused with 4% paraformaldehyde (PFA), and the brains were removed. Samples were flash frozen and cryosectioned coronally at 20 μm slice thickness.
Sections were post-fixed with 4% PFA and stained for astrocytes using rabbit anti-GFAP antibody (glial fibrillary acidic protein, Dako Z0334, 1:500), for demyelination using mouse anti-PLP (Millipore MAB388, 1:200), for axonal degeneration using rabbit anti-TUJ1 (Covance PRB435P, 1:200), for microglia using mouse anti-CD11B and mouse anti-CD68 (Serotec MCA27512 and MCA341R, 1:200 each), for macrophages using rat anti-F4/80 (Millipore MCA497GA, 1:200). Secondary antibodies used were donkey anti-rabbit AlexaFluor 594 (1:500), goat antirabbit AlexaFluor.594 (1:400), goat anti-rabbit AlexaFluor 488 (1:400), goat anti-mouse 488 (1:400), and goat anti-rat 594 (1:400). Histological images were generated using a Zeiss Apotome 2 fluorescent microscope and the manufacturer's software, with the intensity normalized to the maximum fluorescence (automatic units).
Image processing
MR images were generated using custom programs written in MatLab. Maps for onVDMP CEST were generated by fitting the CEST signal generated at the 8 mixing times using a 3-pool Bloch model to obtain the contribution of fast-exchanging protons as performed previously (Xiang et al., 2016; Xu et al., 2014 Xu et al., , 2017 . Maps for CW and APT were generated by calculating the magnetization transfer asymmetry at frequencies AE0.4 to AE6 ppm and AE3.2 to AE4.0 ppm (at intervals of 0.4 ppm), respectively, similar to previous reports (Li et al., 2017) . Analysis of hyper-and hypo-intensities were performed using Image J/FIJI. Regions of interest (ROIs) were defined based on the Allen Atlas (www.brain-map.org), the assignment of which has been provided in the following repository [dataset] (https://doi.org/10.17632/sr567vff6p.1). This EAE model does not result in ventriculomegaly nor brain atrophy at the time-points assessed (Aharoni et al., 2013; MacKenzie-Graham et al., 2012) . Hence, segmentation of ROIs was not adjusted over time.
Statistics
Animal groups were shown to be normally distributed based on the Shapiro-Wilk test. Multi-way analysis of variance with a Tukey post-hoc or a student t-test was used for comparison using GraphPad software. In all cases, p < 0.05 was considered statistically significant.
Data sharing
The data and code that support the findings of this study are available in the following repository [dataset] (https://doi.org/10.17632/sr5 67vff6p.1) or on request from the corresponding author.
Results
We first evaluated the ability of onVDMP CEST MRI to detect alterations in the cerebral forebrain of EAE mice. The slice characterized was positioned 0-2 mm posterior to bregma, permitting the assessment of regions involved in hindlimb motor function: the corpus callosum (Zhou et al., 2013) , lateral striatum (Hunnicutt et al., 2016; Melzer et al., 2017) , sensorimotor cortex (Zhou et al., 2013) , and thalamus (Pan et al., 2010) . For non-motor functions the amygdala, auditory cortex, hippocampus, hypothalamus, and parietal cortex were identified along with the ventricular system (3rd ventricle). The onVDMP signal was significantly lower in EAE mice 12-13 days post induction (DPI) compared to age-matched naïve mice in the corpus callosum and the hypothalamus (Fig. 1 ). Immunohistological analysis in these mice at 29 DPI revealed significantly higher expression of the astrocyte activation marker GFAP, a pathological marker of multiple sclerosis observed throughout the CNS of EAE mice (Luo et al., 2008; Picard-Riera et al., 2002; Zheng and Bizzozero, 2010) , in these regions (Fig. 2) . Stellate morphology indicative of astrogliosis was observed in the corpus callosum of EAE mice. Microglial activation, as indicated by increased CD11B/CD68 immunoreactivity, was also observed in this location (Suppl. Figure 1 ). Immune cell infiltration was minimal at this site. In addition, axon or myelin loss was not observed. All of these histological observations are consistent with prior reports in the literature (Brown and Sawchenko, 2007; Luo et al., 2008) . Time-matched histology, i.e. MRI at 14 DPI and sacrifice at 15 DPI, indicated that the onVDMP signal changed during or after glial activation (Suppl. Figure 2) .
We next investigated whether the onVDMP CEST signal could predict paralysis progression. Although a change in the onVDMP CEST signal in the 3rd ventricle consistently preceded paralysis (10-12 DPI), it weakly correlated with paralysis severity metrics (maximum score (0-5 scale; R ¼ À0.436; p ¼ 0.463), cumulative score (0-28 DPI; R ¼ À0.524; p ¼ 0.365) and number of severe days (clinical score !2.5; R ¼ À0.526; p ¼ 0.363)) ( Fig. 3) . Similar temporal trends of the onVDMP CEST signal were seen in other ventricular structures of the CNS (Fig. 4a ). Alterations in the ventricle were only observed in EAE mice exhibiting paralysis ( Fig. 4b ). Mice that received vaccine lacking the MOG 35-55 antigen (CFA only) and vaccinated mice that did not experience paralysis (subclinical EAE) did not significantly differ from naïve mice.
We then assessed the potential of onVDMP CEST signal changes as a predictive imaging biomarker for disease progression. Changes in onVDMP CEST signal of the 3rd ventricle during paralysis progression were consistently observed in three independent experiments (Table 1) . Unlike in the 3rd ventricle, alterations of the onVDMP CEST signal in parenchymal regions were typically inconsistent amongst these mice. Of all regions assessed, the corpus callosum had the highest observed incidence (2 out of 3 cohorts), and both the auditory cortex and hypothalamus had the lowest (0 out of 3 cohorts). The heterogeneity amongst cohorts was not due to measurement errors as the coefficients of variance of these regions in naïve mice were small with averages ranging from 4% to 11% (Suppl. Table 1 ). We then characterized where and when the onVDMP CEST signal changed during EAE disease progression. Alterations in the onVDMP CEST signal were observed throughout the entire CNS including the 3rd ventricle and multiple regions with known astrogliosis in the EAE model (Luo et al., 2008; Picard-Riera et al., 2002; Zheng and Bizzozero, 2010) that are associated with hindlimb motor function: the corpus callosum (white matter tract), the lateral striatum (basal ganglion), the cerebellum, and Rexed laminae 7-9 (ventral horn) ( Fig. 5 ). All regions having an onVDMP CEST signal showed transiently lower intensity prior to (10-12 DPI) and/or during (17-19 DPI) disease progression, but then restored to naïve levels (by 24-26 DPI).
Changes in the onVDMP CEST signal during disease progression (10-26 DPI) were then compared to conventional MRI techniques used clinically (T1-w, T2-w, and T2*-w MRI), and two clinically-used CEST MRI techniques, i.e., CW CEST and APT CEST, for two independent cohorts (Table 2) . Few changes in MRI signal were seen prior to onset of paralysis (clinical score <1, 10-12 DPI). Signal changes at this time for motor-related regions included the thalamus (CW CEST and APT CEST) and the lateral striatum (CW CEST). Alterations in non-motor regions included the auditory (APT CEST) and piriform (onVDMP CEST) cortices, and the amygdala (T2*-w MRI). Interestingly, the only MRI signal that consistently predicted paralysis in EAE was onVDMP CEST of the 3rd ventricle, which is not known to play a role in motor function. As paralysis progressed in EAE mice, the number of MRI modalities with significantly altered images and the number of regions with altered MRI signal increased. While paralysis was progressing (17-19 DPI), changes began to appear on T2-w MRI, consistent with previous reports (Aharoni et al., 2013) , and included motor-regulating regions of the corpus callosum and somatosensory cortex. These alterations were also observed in onVDMP CEST images. Differences in MRI signal for the amygdala (T2*-w and onVDMP CEST) and parietal cortex (onVDMP CEST) were observed at this time point. However, differences were not yet seen on T1-w images compared to naïve mice. Similar to before paralysis onset, onVDMP CEST of the 3rd ventricle showed the only MRI signal that consistently differed from naïve mice during paralysis progression. After paralysis had stabilized in EAE mice (24-26 DPI), changes were observed for all MRI techniques assessed. Notably, of the 10 parenchymal structures assessed, the amygdala and thalamus were the only regions that changed in signal in EAE mice as paralysis progressed for all 6 imaging modalities. T1-and T2-w images after paralysis progression differed from those prior to progression and from naïve mice in nearly all regions assessed. Changes in T2*-w and onVDMP CEST signal were primarily observed in deep grey structures including the amygdala, lateral striatum, and thalamus. Differences in onVDMP CEST signal before and after paralysis progression were seen throughout the entire brain, i.e., in cortical (auditory, parietal, piriform) and deep grey (amygdala, hypothalamus, thalamus) structures. Regions that changed during paralysis progression for both studies were the hypothalamus (T1-w) and the amygdala (T2*-w and CW CEST).
Lesions were occasionally observed in the cerebrum of EAE-induced mice. In the forebrain slice characterized in this study, a single large lesion was visible on T2-w, T2*-w, APT CEST, and onVDMP CEST images, but not on corresponding T1-w or CW CEST images (Fig. 6 ). Comparing the MR images indicated heterogeneity within the lesion similar to MS (By et al., 2018b; Dula et al., 2011) . In the onVDMP CEST image, this region was hypointense (blue) compared to the contralateral side. In the APT CEST image this region was hypointense (blue) in the dorsal portion, yet isointense in the ventral portion compared to the contralateral side. Interestingly, alterations in CEST signal were also seen in areas adjacent to the lesion that were not observed on T2-and T2*-w images.
Discussion
The development of MRI techniques based on endogenous contrast instead of using contrast agents for monitoring MS disease progression has recently gained attention due to reports of safety concerns upon repeated administration of gadolinium. Gd has been found to be retained in the brain long after administration (Kartamihardja et al., 2016) . Additionally, its repeated use has been associated with brain and renal damage (Ariyani et al., 2017; Grobner, 2006) . T1-and T2-w MRI are techniques used routinely in the clinic to monitor neurodegenerative diseases, including MS. However, they detect pathological changes that occur later during lesion formation, e.g. demyelination and edema (Wolfgang et al., 1997) . Hence, development of alternative MRI methods based on endogenous contrast is warranted. Susceptibility (T2*)-weighted imaging, diffusion tensor imaging (DTI) and magnetization transfer ratio (MTR) imaging each have unique sensitivities to late stage disease markers: iron redistribution, axonal degeneration, and demyelination (Enzinger et al., 2015) , respectively. All three imaging methods have been widely used in MS patients (Cercignani et al., 2001 ; Mohit et al., 2007) . More recently, Aharoni and colleagues characterized DTI and MTR signals in an EAE mouse model and correlated their changes with demyelination (Aharoni et al., 2013) . Here, we expanded the MRI portfolio of imaging endogenous contrast to CW CEST, APT CEST, and onVDMP CEST MRI.
CEST MRI can monitor the alterations in metabolite content that has been shown to occur early in MS pathology with higher spatial resolution than 1 H MRS. Higher lactate and glutamate levels are often featured in normal appearing matter and MS lesions, and these changes have been in part attributed to activated glia cells, i.e. astrocytes (Nijland et al., 2014 (Nijland et al., , 2015 Zeis et al., 2015b) and microglia (Tisell et al., 2013; Vercellino et al., 2007) , respectively. Interestingly, it has been reported that glial activation can occur independently of immune cell infiltration in MS and EAE (Brown and Sawchenko, 2007; Tanuma et al., 2006) , prompting the need to develop MRI methods that can monitor this aspect of the pathophysiology. The brain slice characterized in this report (approximately 1 mm posterior from bregma) undergoes glial activation in the EAE model without immune cell infiltration or neurodegeneration (Brown and Sawchenko, 2007; Luo et al., 2008) , which we confirmed histologically.
The onVDMP CEST MRI signal changes in the 3rd ventricle preceded paralysis progression, yet its signal did not correlate with paralysis severity. Changes in the 3rd ventricle coincided with changes in regions known to control hindlimb function throughout the CNS: the cerebrum (corpus callosum, striatum), the cerebellum (arbor vitae), and the spinal cord (ventral horn). However, we observed MRI alterations in regions responsible for processing sensory (olfactory), emotional (amygdala), and cognitive (hippocampus) stimuli as well. EAE symptoms reported in the literature have included alterations in hindlimb function (movement), pain response, taste (senses), anxiety (emotion), and memory (cognition) (Acharjee et al., 2013; Kim et al., 2012; Olechowski et al., 2013; Pollak et al., 2000) . Similarly, those experienced by MS patients range from paralysis (Carl et al., 2000) to altered smell and taste (Schmidt et al., 2011) to fatigue and memory impairment (Morrow et al., 2009) . We postulate that the pathological events responsible for altering the MRI signatures in all these brain regions contribute to the changes seen in the 3rd ventricle. The MRI modalities assessed in this report can non-invasively monitor damage in regions of the brain that lack clinical symptoms and tests by detecting changes in the molecular composition of the central nervous system, making it a promising tool for monitoring MS.
We found monitoring the 3rd ventricle using onVDMP CEST MRI to be a reliable predictor of EAE. In contrast the MRI signature of the parenchymal regions over the course of EAE varied greatly between our cohorts. The two exceptions were the amygdala (T2*-w and CW CEST MRI) and the hypothalamus (T1-w MRI), both part of the limbic system that controls cognitive behavior. The limbic system and other deep grey structures have been reported to experience damage early on during EAE disease progression (Acharjee et al., 2013) and in MS (Audoin et al., 2010a) . Furthermore, inflammation in these regions has been found to coincide with cognitive behavior changes (Acharjee et al., 2013) . In clinical practice, the primary methods for diagnosing and monitoring MS is the observation of clinical manifestations and the detection of new lesions using Gd-enhanced MRI . However, the lesion distributions reported in the literature reveal widespread, unpredictable locations in EAE (Belloli et al., 2018) and in MS (Vellinga et al., 2009) . In combination with their heterogeneous shape, searching for lesions in the CNS is analogous to finding needles in a haystack. Due to the difficulty in detecting lesions, diagnosis of MS is often limited to its clinical manifestation. Some groups have attempted to improve lesion detection with the development of novel contrast agents with improved sensitivity for BBB breakdown (Ladewig et al., 2009) . Others have developed contrast (Chen et al., 2008) and labeling (Floris et al., 2004) agents that monitor inflammation, particularly macrophage infiltration. The variation in signal amongst cohorts was appreciable; therefore, a reference may potentially be needed to normalize the signal for future applications and clinical translation. However, unlike Gd-enhanced and other lesion-detecting MRI approaches, onVDMP CEST MRI of the 3rd ventricle does not require a priori knowledge of the lesion's location to monitor disease activity, and thus, is a potentially more practical approach to monitoring MS as it reduces imaging and analysis time. Changes in endogenous MRI contrast over the course of EAE differed greatly amongst the co-registered modalities, likely due to differential sensitivities to the molecular changes that occur during lesion development. In MS, T1-and T2-w MRI are used clinically to monitor edema formation and myelin content after the immunological attack in MS (Wolfgang et al., 1997) . Similarly, in EAE, T1-and T2-w MRI has been associated with neuron and myelin loss. Gradual neuron loss has been observed from 12 DPI onwards (Soulika et al., 2009) . Progressive myelin loss has been reported from 9 DPI onwards (Berard Jennifer et al., 2009) . In this report neither imaging modality had significant changes before paralysis progression. Changes were observed by 17-19 DPI using T2-w MRI in several regions including the hippocampus, which has been shown histologically to experience inflammation and neuron loss around this time (Ziehn et al., 2010) . However, both MRI modalities revealed diffuse changes throughout the parenchyma after paralysis progression, i.e. significant changes in T1 and T2 intensity by 24-26 DPI, consistent with prior reports in EAE (Aharoni et al., 2013) and MS (Mohit et al., 2007) . Changes in the amygdala, striatum, and thalamus were seen early during the course of EAE using these MRI modalities, beginning at 10-12 DPI, consistent with reports that damage to the limbic and deep grey structures are the first signs of MS (Audoin et al., 2010b) . Changes in T2* intensity of the amygdala is consistent with reports of alterations in T2* of deep grey matter structures in MS patients (Mohit et al., 2007) . We postulate that changes in T2* of the amygdale reflect iron liberation upon demyelination as T2*-w MRI has been shown to correlate with this phenomenon in MS (Li et al., 2015) .
CEST MRI modalities can detect exchangeable protons, a feature which has been explored pre-clinically to monitor the presence of metabolites and other small biomolecules (Bagga et al., 2018; Davis et al., 2015; Haris et al., 2013; Kejia et al., 2015) . Transient metabolic alterations during immunological attack (lesion formation) have been observed in MS patients (Lutz et al., 2007) and would explain the transient change in onVDMP CEST signal which is restored to naïve levels at the chronic stage. Changes in CW, APT and onVDMP CEST MRI started to appear prior to paralysis onset (10-12 DPI), consistent with changes in brain metabolism reported previously (after 14 DPI (Ibrahim et al., 2001) ). onVDMP CEST MRI has previously been shown to be sensitive to glutamate (Xu et al., 2017) , one of the most concentrated metabolites in the brain (Agrawal et al., 1968; Perry et al., 1981) . Both focal lesions and diffuse damage were detected using CEST MRI. Overall, assessing the brain using multiple CEST MRI modalities may expand the visual information of parenchymal damage that occurs early on during the progression of disease in EAE.
Conclusions
These studies present a novel MRI modality to monitor EAE disease progression. onVDMP CEST MRI signal in the parenchyma changed over the course of EAE. The spatiotemporal signature of onVDMP CEST MRI differed from that of T1-w, T2-w, T2*-w, CW CEST, and APT CEST. onVDMP CEST MRI of the parenchyma provided visual information on EAE progression that complemented that of more established endogenous MRI methods. Tracking changes in onVDMP CEST MRI of the 3rd ventricle was demonstrated to be a reliable strategy for predicting Table 2 Alterations in endogenous MRI signal during EAE disease progression. Comparison of CW, APT, and onVDMP CEST MRI to conventional MRI methods for evaluating the occurrence and location of EAE progression (disease activity).^The days post induction (DPI) for EAE stages are 10-12 DPI for pre-onset, 17-19 DPI for acute, and 24-26 for chronic. þþ ¼ p < 0.05 in two chohorts. þ ¼ p < 0.05 in one cohort.
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disease. This approach did not require a priori knowledge of injury location, which may permit potentially faster acquisition, analysis and interpretation of MRI for assessment of disease activity. Future studies wherein acquisition parameters are optimized and saturation power is minimized will need to be performed and an appropriate reference to normalize signal across machines will need to be identified to determine whether our findings in the EAE animal model can translate to studies in clinical MS. 
